FDA approves GSK vaccine to combat meningococcal infections
Meningococcal infections can lead to severe, sometimes deadly, bloodstream infections, and severe swelling in the brain and ...
ENDPOINTS NEWS14h
GSK fol­lows Pfiz­er in meningo­coc­cal vac­cine race with new FDA nod
GSK has snagged FDA approval for its 5-in-1 meningococcal vaccine, propelling it to a familiar position: rivaling Pfizer.
US FDA approves GSK's combo meningococcal vaccine
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
FiercePharma16h
With new FDA approval, GSK joins Pfizer in the 5-in-1 meningococcal vaccine ring
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
ROSEN, A LEADING NATIONAL FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Rosen Law Firm PAWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers ...
GSK Pharma put volume heavy and directionally bearish
Pharma with 2,330 puts trading, or 1.1x expected. Most active are 2/14 weekly 36 puts and 2/28 weekly 36 puts, ...
Hedge fund Citadel takes short position in GSK, FT reports
Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...
GSK plc (NYSE:GSK) Shares Sold by Kingsview Wealth Management LLC
Kingsview Wealth Management LLC lowered its holdings in GSK plc (NYSE:GSK – Free Report) by 11.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange ...
Emma Walmsley Sells 120,653 Shares of GSK plc (LON:GSK) Stock
GSK plc (LON:GSK – Get Free Report) insider Emma Walmsley sold 120,653 shares of the firm’s stock in a transaction on Monday, ...
FierceBiotech3d
GSK plans to move vaccine R&D group from Maryland to the Boston area
After calling Rockville, Maryland, home for more than eight years, GSK's vaccine and infectious disease R&D teams are ...
Drug developer GSK leaving 635K sf life sciences lab near DC
Drug developer GSK is vacating its 635,000-square-foot life sciences lab in Rockville, Maryland, where it was the sole tenant ...
Morgan Stanley starts GSK stock with underweight rating
Morgan Stanley (NYSE:MS) initiated coverage on shares of GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK), a $72.5 billion pharmaceutical giant with a 25-year track record of consistent dividend payments, ...